AWAK Attracts Investment Billions
Singapore-based AWAK Technologies’ miniaturized sorbent platform for PD and HD regenerates dialysate to use up to 90% less fluid. This package was intriguing enough to attract an $11.2B investment from Accuron MedTech—improving its changes of reaching the market!
Read the full article » | Posted 06-12-2017
Related Articles
- VenoStent, Inc. is Recruiting Patients for a Clinical Trial of the SelfWrap Posted 10-14-2025
- Diality Treated its First Patient in the Moda-flx Home IDE PRESCRIBE Cinical Trial Posted 10-14-2025
- eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant Posted 09-15-2025
- The First Artificial Kidney Built in Canada has Ties to London: A Revolution in Care for Patients with Kidney Failure Posted 09-15-2025

